ZA200608178B - Polypeptide sequence involved in the modulation of the immunosuppresive effect of viral proteins - Google Patents

Polypeptide sequence involved in the modulation of the immunosuppresive effect of viral proteins

Info

Publication number
ZA200608178B
ZA200608178B ZA200608178A ZA200608178A ZA200608178B ZA 200608178 B ZA200608178 B ZA 200608178B ZA 200608178 A ZA200608178 A ZA 200608178A ZA 200608178 A ZA200608178 A ZA 200608178A ZA 200608178 B ZA200608178 B ZA 200608178B
Authority
ZA
South Africa
Prior art keywords
modulation
polypeptide sequence
viral proteins
sequence involved
protein
Prior art date
Application number
ZA200608178A
Other languages
English (en)
Inventor
Renard Martial
Mangeney Marianne
Heidmann Thierry
Original Assignee
Roussy Inst Gustave
Centre Nat Rech Scient
Univ Paris Sud Xi
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Roussy Inst Gustave, Centre Nat Rech Scient, Univ Paris Sud Xi filed Critical Roussy Inst Gustave
Publication of ZA200608178B publication Critical patent/ZA200608178B/xx

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K7/00Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04Linear peptides containing only normal peptide links
    • C07K7/08Linear peptides containing only normal peptide links having 12 to 20 amino acids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/14Antivirals for RNA viruses
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • A61P37/06Immunosuppressants, e.g. drugs for graft rejection
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/08Antiallergic agents
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K7/00Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04Linear peptides containing only normal peptide links
    • C07K7/06Linear peptides containing only normal peptide links having 5 to 11 amino acids

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Immunology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Virology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Pulmonology (AREA)
  • Transplantation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
ZA200608178A 2004-03-30 2005-03-30 Polypeptide sequence involved in the modulation of the immunosuppresive effect of viral proteins ZA200608178B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP04290838 2004-03-30

Publications (1)

Publication Number Publication Date
ZA200608178B true ZA200608178B (en) 2008-10-29

Family

ID=34896141

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA200608178A ZA200608178B (en) 2004-03-30 2005-03-30 Polypeptide sequence involved in the modulation of the immunosuppresive effect of viral proteins

Country Status (14)

Country Link
US (2) US8178657B2 (enExample)
EP (1) EP1732585B1 (enExample)
JP (1) JP5060284B2 (enExample)
CN (1) CN1961001B (enExample)
AT (1) ATE472334T1 (enExample)
AU (1) AU2005229411B2 (enExample)
BR (1) BRPI0509497B1 (enExample)
CA (1) CA2561376C (enExample)
DE (1) DE602005022056D1 (enExample)
ES (1) ES2347445T3 (enExample)
IL (1) IL178205A (enExample)
MX (1) MXPA06011272A (enExample)
WO (1) WO2005095442A1 (enExample)
ZA (1) ZA200608178B (enExample)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9777044B2 (en) 2003-05-02 2017-10-03 Centre National De La Recherche Scientifique (Cnrs) GLUT-1 as a receptor for HTLV envelopes and its uses
ATE538802T1 (de) 2005-03-30 2012-01-15 Viroxis Endogener retrovirus und proteine, kodiert durch env-gen, als target für die krebsbehandlung
US20070185025A1 (en) * 2005-09-11 2007-08-09 The Trustees Of Columbia University In The City Of New York Filoviral immunosuppressive peptides and uses thereof
US20080299150A1 (en) * 2007-05-08 2008-12-04 Sankhia Corporation Method and system for processing immuno-competent cells in view of an antiviral therapy, and related therapeutic process
US8323891B2 (en) * 2008-08-01 2012-12-04 Claflin University miRNA triplex formations for the downregulation of viral replication
RU2008140688A (ru) * 2008-10-15 2010-04-20 Михаил Аркадьевич Шурдов (RU) Иммуносупрессивный пептид
JP5624994B2 (ja) 2009-01-09 2014-11-12 サントル ナショナル ドゥ ラ ルシェルシュ シアンティフィク 新たなレセプター結合性リガンド、生物学的対象の細胞の検出におけるその使用
WO2011092199A1 (en) * 2010-01-26 2011-08-04 Institut Gustave Roussy Mutated xmrv env proteins in the immunosuppressive domain
US20130197612A1 (en) 2010-02-26 2013-08-01 Jack W. Lasersohn Electromagnetic Radiation Therapy
WO2012035369A1 (en) * 2010-09-17 2012-03-22 Centre National De La Recherche Scientifique Method for the diagnosis and/or prognosis of inflammatory states
BR112014001287B1 (pt) * 2011-07-20 2020-12-08 Centre National De La Recherche Scientifique vacina recombinante do vírus da leucemia felina contendo gene otimizado do envelope do vírus da leucemia felina
US9636396B2 (en) 2011-12-07 2017-05-02 Centre National De La Recherche Scientifique Mutant human and simian immunodeficiency virus ENV proteins with reduced immunosuppressive properties
CA2856180C (en) 2011-12-07 2022-09-06 Viroxis S.A.S. Mutated lentiviral env proteins and their use as drugs
WO2014195510A1 (en) * 2013-06-07 2014-12-11 Viroxis S.A.S. Mutated non-primate lentiviral env proteins and their use as drugs
EP3309178A4 (en) * 2015-06-11 2019-05-08 Keio University FUSION PROTEIN OR CONJUGATED PROTEIN, CARRIER FOR INTRA-CELLULAR DELIVERY, PARTICLE PEPTIDE, CELL MEMBRANE PERMEATION AMPLIFIER, DNA AND VECTOR
CN108368155A (zh) * 2015-10-01 2018-08-03 爱姆维恩公司 人源性免疫抑制蛋白和肽作为药物的应用
WO2019043127A1 (en) 2017-09-01 2019-03-07 Inprother Aps VACCINE FOR USE IN PROPHYLAXIS AND / OR TREATMENT OF DISEASE
US20210403907A1 (en) 2018-09-18 2021-12-30 Vnv Newco Inc. Arc-based capsids and uses thereof
EP3852813A4 (en) 2018-09-18 2022-06-22 VNV Newco Inc. ARC-BASED CAPSIDS AND THEIR USES
US11129892B1 (en) 2020-05-18 2021-09-28 Vnv Newco Inc. Vaccine compositions comprising endogenous Gag polypeptides
EP4277704A1 (en) * 2021-01-13 2023-11-22 Viroxis Measles-hiv or measles-htlv vaccine
CN121752289A (zh) 2023-04-21 2026-03-27 盈珀治疗有限公司 表面展示抗原的改善表达

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4822606A (en) 1986-04-07 1989-04-18 Duke University Immunosuppressive synthetic peptides and analogs thereof based on retroviral envelope sequences
DE68929419T2 (de) 1988-12-13 2003-04-03 Colorado State University Research Foundation, Fort Collins Prototypische FeLV-Isolate für die Verwendung als Krankheitsmuster oder Impfstoff
FR2771011B1 (fr) * 1997-11-17 2000-01-28 Hippocampe Obtention de vaccins destines a prevenir les effets pathogenes associes a une infection retrovirale
FR2780069B1 (fr) * 1998-06-23 2002-06-28 Inst Nat Sante Rech Med Famille de sequences nucleiques et de sequences proteiques deduites presentant des motifs retroviraux endogenes humains et leurs applications
JP2003512844A (ja) * 1999-10-28 2003-04-08 ユニヴェルシテ・ドゥ・ジュネーブ 多発性硬化症関連スーパー抗原
AU2002230758A1 (en) * 2000-12-11 2002-06-24 Tufts University Treatment and prevention of EBV infection and EBV-associated disorders
GB0112126D0 (en) 2001-05-18 2001-07-11 Allergene Inc Composition

Also Published As

Publication number Publication date
US20080008683A1 (en) 2008-01-10
ES2347445T3 (es) 2010-10-29
JP2008506357A (ja) 2008-03-06
EP1732585B1 (en) 2010-06-30
EP1732585A1 (en) 2006-12-20
WO2005095442A8 (en) 2006-11-02
US20120189647A1 (en) 2012-07-26
BRPI0509497A (pt) 2007-09-11
ATE472334T1 (de) 2010-07-15
CA2561376C (en) 2016-06-21
US8178657B2 (en) 2012-05-15
AU2005229411B2 (en) 2010-11-18
BRPI0509497B1 (pt) 2022-07-19
MXPA06011272A (es) 2007-04-17
AU2005229411A1 (en) 2005-10-13
WO2005095442A1 (en) 2005-10-13
JP5060284B2 (ja) 2012-10-31
CN1961001B (zh) 2012-09-05
IL178205A0 (en) 2006-12-31
US8597657B2 (en) 2013-12-03
CN1961001A (zh) 2007-05-09
CA2561376A1 (en) 2005-10-13
DE602005022056D1 (de) 2010-08-12
IL178205A (en) 2015-05-31

Similar Documents

Publication Publication Date Title
IL178205A0 (en) Polypeptide sequence involved in the modulation of the immunosuppresive effect of viral proteins
WO2005032487A3 (en) Angiotensin-converting enzyme-2 as a receptor for the sars coronavirus
SI1685243T1 (sl) Imortalizirane ptičje celične linije za produkcijo virusov
WO2006136084A8 (en) Fusion proteins of recombinant sars coronavirus structural proteins, their production and uses
EP2395078A3 (en) Covalent tethering of functional groups to proteins and substrates therefor
WO2009108274A3 (en) Methods and compositions for adeno-associated virus (aav) with hi loop mutations
EP4234571A3 (en) Viral vectors with modified transduction profiles and methods of making and using the same
IL187168A (en) Proteins or polypeptides which comprise two identical nanobodies against von willebrand factor, methods for their preparation, pharmaceutical compositions comprising them and their uses
DK1513937T3 (da) Fremgangsmåde til den samtidige produktion af multiple proteiner; vektorer og celler til anvendelse derved
WO2010132092A3 (en) Cytidine deaminase fusions and related methods
MY169472A (en) Refolding of recombinant proteins
MX2009010492A (es) Elementos de vector de expresion recombinante (reves) para mejorar la expresion de proteinas recombinantes en celulas huesped.
MX2022014162A (es) Proteínas de fusión de la proteína de la espícula del coronavirus estabilizadas.
MX2009006398A (es) Genotecas de proteinas de fusion de transferrina.
SG160424A1 (en) Compositions of influenza viral proteins and methods of use thereof
WO2006074233A3 (en) Polypeptides having nucleic acid binding activity and compositions and methods for nucleic acid amplification
MX2009012326A (es) Peptidos de señalizacion.
WO2004024750A3 (en) Cd44-binding ligands
WO2007053188A3 (en) Production of multivalent virus like particles
WO2005003315A3 (en) Compositions and methods for peptide-assisted transfection
DE60114018D1 (de) Von zellen präsentierte peptide
DE602005023181D1 (de) Lentivirusvektoren und deren verwendung
WO2007047504A3 (en) Natriuretic peptide modified transferrin fusion proteins
MX2010000232A (es) Metodos mejorados para la formacion de enlaces disulfuro.
WO2005002501A3 (en) Novel druggable regions in the dengue virus envelope glycoprotein and methods of using the same